Dupixent Class Action Lawsuit 2026: MDL 3180 Status, CTCL Claims, and Why There Is No Settlement Yet
Quick Answer
- Is it legit? Yes. A federal MDL exists for CTCL claims against Dupixent makers Regeneron and Sanofi.
- How much can I get? Not yet determined. No settlement exists and no bellwether verdict has been reached.
- What is the deadline? There is no claim deadline. State statutes of limitation govern individual filing deadlines.
If you used Dupixent and later developed cutaneous T-cell lymphoma, you may be watching a lawsuit that is real but early. The case is In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, before Judge Zahid N. Quraishi in New Jersey federal court .
There is no settlement. There is no claim form. There is no payout amount. What exists is a consolidated pretrial proceeding with dozens of individual injury cases, a stayed discovery schedule, and a leadership motion still pending as of October 2026 .
This article explains what MDL 3180 actually is, who may have a claim, why any website quoting a Dupixent payout number is guessing, and what the court record shows will happen next.
The Facts
| Case | In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180 |
| Court | U.S. District Court for the District of New Jersey, Judge Zahid N. Quraishi |
| Status | Consolidated pretrial proceedings. Discovery stayed. No settlement. No trial date. |
| Fund Size | Not yet confirmed. No settlement fund exists. |
| Est. Per Person | Not yet determined. No settlement matrix has been negotiated. |
| Claim Deadline | None. State statutes of limitation apply to individual filings. |
| Administrator | Not yet appointed. No claims administration exists. |
| Proof Needed | Medical records linking Dupixent use to a CTCL diagnosis, plus pathology confirmation. |
Is the Dupixent class action lawsuit real or a scam?
The lawsuit is real, but it is not a class action in the way most people use that phrase. MDL 3180 is a multidistrict litigation, a procedural tool that gathers federal injury cases before one judge for pretrial coordination .
The distinction matters for you. In a class action, one plaintiff represents everyone and a single settlement covers the group. In an MDL, each plaintiff keeps an individual case. There is no automatic inclusion, no claims deadline, and no guaranteed payout.
Scams feed on that confusion. A website promising a “Dupixent settlement check” is either describing a different case or inventing a number. The court docket as of October 2026 shows no settlement, no verdict, and no ruling on the merits .
Key Takeaway: MDL 3180 is a real federal consolidation of individual CTCL injury claims, not a class action with a settlement fund, and no legitimate claims process exists yet.
How much will the Dupixent lawsuit payout be?
The per-person payout is not yet determined because no settlement program exists. No judge or jury has decided whether Dupixent causes CTCL, and no bellwether trial has been scheduled .
Any figure you see online is not from this litigation. Settlement matrices in drug MDLs are built after bellwether verdicts or during global negotiations. They use injury tiers, point adjustments for diagnosis severity, treatment burden, exposure duration, and proof quality .
| Factor | How It Typically Affects a Future Payout |
| Diagnosis type and stage | CTCL stage at diagnosis and whether it is biopsy-confirmed. |
| Treatment burden | Chemotherapy, radiation, transplant, or ongoing monitoring. |
| Dupixent exposure | How long you used the drug before diagnosis. |
| Proof quality | Prescription records, pathology reports, and the timeline linking the two. |
| Timing | Whether your claim is filed inside your state’s statute of limitations. |
No one can tell you a dollar amount today. The Sanofi half-year financial report for 2026 states that it is “not possible, at this stage, to assess reliably the outcome of these ongoing cases” .
Reality Check: No one will text you a Dupixent settlement link. Filing a claim in a drug MDL does not cost you money upfront, and legitimate lawyers work on contingency, meaning they get paid only if you recover. Any website quoting a specific Dupixent payout number is not describing this litigation, because no such number exists.
Who qualifies for the Dupixent lawsuit?
You may qualify if you used Dupixent (dupilumab) as prescribed and were later diagnosed with cutaneous T-cell lymphoma (CTCL) or a related T-cell lymphoma . The MDL currently centers on CTCL, though the Panel deferred the question of whether other T-cell lymphomas belong .
The medication is commonly prescribed for atopic dermatitis (eczema) and asthma. The lawsuits allege that Regeneron and Sanofi failed to warn that Dupixent can cause or accelerate CTCL despite being aware of a potential link .
| Qualifying Factors | Not Enough on Their Own |
| Used Dupixent as prescribed | Dupixent use without a lymphoma diagnosis |
| Diagnosed with CTCL or related T-cell lymphoma | A lymphoma diagnosis without Dupixent use |
| Medical records connecting the two | B-cell or Hodgkin’s lymphoma (excluded from MDL) |
| Claim filed within your state’s deadline | A diagnosis outside the statute of limitations |
The FDA identified a potential safety signal in January 2025 and its evaluation is ongoing. Dupixent’s label does not currently warn about lymphoma .
How do I file a Dupixent lawsuit?
You cannot file a claim through a settlement administrator, because none exists. To pursue a Dupixent injury claim, you must file an individual lawsuit in state or federal court, typically with the help of a lawyer who handles drug injury cases.
Here are the steps:
- Gather your medical records. You need pathology reports confirming CTCL and prescription records showing Dupixent use.
- Establish the timeline. The dates of Dupixent use and the CTCL diagnosis must be documented.
- Check your state’s statute of limitations. These deadlines vary widely and some are as short as one year .
- Consult a drug injury lawyer. Most work on contingency and offer free case reviews.
- File your case in the appropriate court. Federal cases may be directly filed into MDL 3180 or transferred in.
- Do not stop taking Dupixent without talking to your doctor. Filing a lawsuit does not require you to stop your medication .
Filing a lawsuit is not like returning a defective product to a store. You do not fill out a form and wait for a refund. You become a party to a legal proceeding, and your lawyer builds a case around your medical records.
Key Takeaway: There is no claim form to file for a Dupixent settlement. The only path is an individual lawsuit filed within your state’s deadline, and the clock may already be running.
What is the deadline to file a Dupixent lawsuit?
There is no single deadline. Each state sets its own statute of limitations for product liability and personal injury claims, and the rules for when the clock starts differ .
Some states use a discovery rule, meaning the clock starts when you knew or should have known about the link between Dupixent and your diagnosis. Because the FDA’s safety signal became public in January 2025, some patients’ clocks may have started then .
| State Example | General Deadline | Notes |
| Alabama | Two years from discovery | Discovery rule applies; clock may start at FDA signal or diagnosis. |
| New Jersey | Varies by claim type | MDL forum state; consult a lawyer for your specific timeline. |
| Your state | Not yet confirmed | Check with a licensed attorney in your jurisdiction. |
Do not wait for a settlement announcement. By the time a global settlement is negotiated, the statute of limitations may have expired for many potential claimants. Filing now preserves your position.
When will Dupixent settlement checks be mailed?
There is no confirmed payment window, because no settlement exists. The litigation is in its earliest pretrial phase, with discovery stayed under Initial Procedure Order No. 1 and no bellwether schedule set .
Drug MDLs commonly run for years. A settlement, if one comes, would follow bellwether trials or global negotiations. The court’s next scheduled status conferences are December 17, 2026, February 22, 2027, and May 17, 2027 .
No one can tell you when checks will mail. Anyone who does is selling something.
What is the Dupixent lawsuit about?
The lawsuits allege that Dupixent, a blockbuster drug for eczema and asthma, causes or accelerates cutaneous T-cell lymphoma. Plaintiffs claim Regeneron and Sanofi knew about the risk and failed to warn doctors and patients .
The MDL was created on June 4, 2026, when the Judicial Panel on Multidistrict Litigation transferred 14 actions to New Jersey . By October 1, 2026, the Panel reported 38 actions pending in MDL 3180 .
Sanofi’s 2026 half-year report states that approximately 30 product liability cases were filed in federal courts, plus eight in New Jersey state court . The complaints assert strict liability, negligence, and fraudulent misrepresentation .
What happens next in the Dupixent litigation?
The next stages are procedural, not substantive. No trial is scheduled and no settlement talks have been disclosed.
- November 2, 2026: Motion to appoint plaintiffs’ leadership is set for consideration. The motion is unopposed .
- December 17, 2026: Status conference before Judge Quraishi .
- February 22, 2027: Status conference .
- May 17, 2027: In-person status conference in Trenton .
- TBD: Leadership appointment, discovery schedule, bellwether selection, and any settlement discussions.
Frequently Asked Questions
Is there a Dupixent class action settlement?
No. As of October 2026, there is no settlement in MDL 3180. The litigation is in its earliest pretrial phase.
How much is the Dupixent lawsuit worth per person?
Not yet determined. No settlement matrix exists, and no bellwether verdict has set a negotiating range.
Do I need a lawyer to file a Dupixent claim?
Yes, realistically. Drug injury MDLs involve complex medical evidence and procedural rules that are not designed for self-representation.
What is the deadline to file a Dupixent lawsuit?
There is no single deadline. Each state has its own statute of limitations, and some are as short as one year from discovery.
Can I join the Dupixent lawsuit if I was diagnosed with a different lymphoma?
The MDL currently centers on CTCL. The Panel deferred the question of whether other T-cell lymphomas belong . B-cell and Hodgkin’s lymphoma are excluded.
Is Dupixent still on the market?
Yes. The FDA has not withdrawn the drug, and its label does not currently warn about lymphoma. The agency’s safety evaluation is ongoing.
What evidence do I need for a Dupixent claim?
Pathology reports confirming CTCL, prescription records showing Dupixent use, and a documented timeline connecting the two.
When will Dupixent lawsuits go to trial?
No bellwether trial date has been set. Drug MDLs typically take years to reach trial or settlement.
What You Should Do Now
If you used Dupixent and were diagnosed with CTCL, do not wait for a settlement headline. Talk to a drug injury lawyer about your state’s deadline. Gather your pathology reports and prescription records now.
The most important fact is the one that applies to you: your state’s statute of limitations. That clock is running whether or not a settlement exists.
